

The central noradrenergic system: an overview

M Viljoen, A Panzer

Department of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa

Abstract

The central noradrenergic system belongs to a group of brainstem neuromodulatory systems previously referred to as the ascending reticular activating system. In this article a heuristic model is presented of the central noradrenergic system depicting the major projections to other cerebral areas, its interactions with other neuromodulatory systems, mechanisms through which it can influence cerebral function, as well as the major functions and disorders associated with alterations in central noradrenergic activity. It is not the aim of this paper to provide fine detail on the various aspects, but rather to provide a concise overview where structure and function, as well as the interactions with other systems are brought together. The contents of the paper are summarized in a diagram.

Key words: Central noradrenergic system; Neuromodulatory; Brainstem

Received: 27-07-2006

Accepted: 10-10-2006

Introduction

The majority of central noradrenergic neurons are situated in the brainstem where they form part of the brainstem neuromodulatory systems. The brainstem neuromodulatory systems include cell groups such as the noradrenergic neurons, the dopaminergic neurons, the cholinergic neurons and the serotonergic neurons. The cell bodies of the ascending projections of these systems were erstwhile seen as part of the ascending reticular activating system.¹ In wider context the brainstem neuromodulatory systems form part of the cerebral arousal system that includes a) the brainstem arousal systems (the reticular formation, the brainstem cholinergic, noradrenergic, dopaminergic and serotonergic systems), b) the thalamocortical activating system, c) the hypothalamic arousal systems and d) the basal forebrain wake and sleep promoting systems.² The primary functions of the brainstem neuromodulatory systems are that of modulation and regulation of the activity levels of other CNS systems where they increase or decrease activity levels of other neurons and synchronize or desynchronize other systems. As part of the brainstem arousal systems these systems overlap in function, but differ in their contributions under various conditions and in specific waking behaviours.² The importance of the brainstem neuromodulatory systems'

influence on higher brain centers is perhaps best illustrated by the fact that the cerebral cortex is unable to maintain consciousness without stimulatory influences from the brainstem modulatory systems.³ Their effects on the behavioural functions are further demonstrated by the many psychiatric disturbances associated with malfunctioning in one or more of the brainstem neuromodulatory systems. Typical of these neuromodulatory systems is the vastness of their postsynaptic connections on other cerebral structures and the fact that they often propagate their impulses to the rest of the CNS through volume transmission where the neurotransmitters are released into the extracellular fluid⁴ – both mechanisms that vastly increase the scope of their influences.

The heuristic model presented in this overview focuses on the central noradrenergic system, a system generally associated with cortical activation, increased cerebral responsiveness to stimuli, an increase in the rate at which the brain processes information and the ability to focus attention on relevant and ignore irrelevant incoming information. The content of this text is summarized in Figure 1.

Location of the central noradrenergic system, its major projections and its connection with the peripheral sympathetic nervous system


The sympathetic nervous system and the adrenomedullary system are collectively referred to as the sympathoadrenomedullary system or SAM-axis, while the central noradrenergic system is often simply referred to by its abbreviation, i.e., the CNA system. The central noradrenergic

Correspondence:

Prof M Viljoen
Department of Physiology, P O Box 2034, Faculty of Medicine,
University of Pretoria, Pretoria, 0001. South Africa.
email: mviljoen@medic.ac.up.za.

Figure 1: The brain stem noradrenergic systems.

The diagram shows the two major brain stem noradrenergic systems (1&2), their projections to other CNS structures (1&2), specific effects of the noradrenergic systems on cerebral structure and function (3), the influence of psychological events on the noradrenergic system (4), functions and disorders associated with noradrenergic activity (5) and other brain stem neuromodulatory systems with which the central noradrenergic system interacts (6).



system and the peripheral noradrenergic system are generally thought of as two separate systems sharing the same major neurotransmitter. Yet, activation of the central noradrenergic (CNA) neurons, as occurs during any period of marked emotional arousal, is generally paralleled by simultaneous activation of the peripheral noradrenergic (sympathetic nervous) and adrenomedullary systems.⁵ Symptoms of sympathetic hyperactivity are also often equated with an increase in central noradrenergic activation. However, scientific recognition of a direct influence of the central noradrenergic system on peripheral sympathetic nervous system activity is not well documented in the literature. There are, nonetheless, indications that a direct link does exist. The concomitant increase in activity of the SAM-axis, at times of emotion-associated CNA hyperactivity, is said to involve neural structures such as the amygdala, the ascending reticular activating system, descending projections from the central noradrenergic nuclei to the brainstem and spinal cord, posterior hypothalamic control areas, as well as the nucleus paragigantocellularis.^{6,7} It has also been shown that cerebral-derived noradrenaline can have a sympatho-excitatory role in the regulation of preganglionic neurons of, at least, the thoracolumbar spinal cord, and that some of the effects of centrally-produced noradrenaline on peripheral sympathetic function may be mediated through spill-over of noradrenaline from the subcortical areas into the plasma.^{8,9} In short, common observations as well as scientific evidence support the notion of a sympatho-excitatory role for the central noradrenergic system.

The two major divisions of the brainstem noradrenergic system and their projections to the rest of the CNS are depicted in the middle-right side of the diagram (1&2). The cell bodies of the central noradrenergic neurons are situated in the pons and medulla. The major groups are a) the locus coeruleus and subcoeruleus found near the floor of the fourth ventricle and b) those located in the lateral parts of the medullary reticular formation and in nuclei associated with cranial nerves such as the solitary nucleus and dorsal motor nucleus of vagus.^{3,10} Ascending and descending fibers from these major sites of origin innervate virtually the whole cerebral cortex, the brainstem, the thalamus and hypothalamus, limbic forebrain structures, as well as the cerebellum and spinal cord. The locus coeruleus nuclei (locus coeruleus = meaning blue spot) are responsible for almost the entire output to the cerebral cortex, while the lateral reticular formation neurons provide the output to the spinal cord.¹⁰

Interaction with other neuromodulatory systems

The brainstem noradrenergic system, as previously mentioned, forms part of what was generally referred to as the ascending reticular activation system (ARAS). The neuromodulatory aminergic systems interact in a complex way – as yet not completely understood.¹ Several reviews and other publications are available that endorse the fact that the neuromodulatory substances directly or indirectly influence the release of each other. Examples include the interaction between noradrenaline and serotonin¹¹, the effect of noradrenaline on dopamine release¹², the interactions between corticotropin-releasing hormone (CRH), noradrenaline and serotonin¹³, the regulatory influence of noradrenergic neurons on GABA-ergic neurons and histaminergic neurons¹⁴, and many others. In addition, several

higher brain centers each receive modulatory inputs from a number of brainstem neuromodulatory systems¹⁵ – yet another way of functional cooperation between these systems. Some of the interacting neuromodulatory systems are depicted in Figure 1, No 1.

The individual neuromodulatory systems show hemispheric asymmetry in their widespread projections to higher cerebral areas. For instance, the noradrenergic projections to the right hemisphere are more prominent than those to the left hemisphere.¹ This phenomenon is speculated to play a role in handedness. It is also speculated that the asymmetrical distribution of noradrenergic projections could play a role in the observed association between handedness and the vulnerability to immune-related disturbances. The prevalence of disorders such as myasthenia gravis, asthma, hay fever, eczema, migraine, coeliac and Crohn's disease, as well as Hashimoto's thyroiditis is, for instance, significantly higher among left-handers than among right-handers.^{16,17}

In addition to the interactions between the brainstem noradrenergic nuclei and other neurohormonal systems of the brainstem, noradrenergic neurons have a close interaction with the central corticotropin-releasing hormone system in the brainstem and elsewhere. A positive reverberating feedback mechanism is for instance known to exist between the noradrenergic neurons of the locus coeruleus and the central corticotropin-releasing hormone neurons.¹⁸ Substances that stimulate the noradrenergic cell bodies will, in general, also stimulate CRH cell bodies, and inhibitory factors will suppress both systems.¹⁸ Although the concept of a bi-directional stimulatory influence between the CRH and central noradrenergic systems is well established, to the extent that the sensitivity of a feed-forward loop between them has been proposed as an underlying cause of clinical depression, some uncertainty still exists – such as whether intermediates are involved in these bi-directional stimulatory actions.¹⁹ The interactions between the central noradrenergic system and other neuroendocrine modulatory systems are depicted on the upper-left hand side of the diagram (6a-6f).

As interactions between the neurohormonal modulatory systems can lead to modulation of their respective influences on cerebral function and behavior it is impossible to imagine that a disturbance in one system, or for that matter medications that influence one system, could act in isolation from other systems. Many examples of co-dysregulation of these systems can, in fact, be found such as the co-dysregulation of serotonergic and noradrenergic function in depression and anxiety disorders²⁰, and the co-dysregulation of noradrenaline, serotonin, GABA, CRH, and glutamine in depression and epilepsy.²¹ In most instances we are still far from absolute identification of the primary causative system. Nevertheless, the central noradrenergic system is by several theories postulated as central to a number of psychiatric disturbances. The best known theories are probably related to mood disorders, but others are also known, such as a recent theory (based on the fact that the central noradrenergic system influences both the nigrostriatal dopaminergic and basalocortical cholinergic systems) postulating that the activity of the noradrenergic system plays a central role in the progression of a number of neurodegenerative disorders including Parkinson's and Alzheimer's disease.²²

Mechanisms of influence on cerebral and behavioural functions

Specific effects of the noradrenergic influence on cerebral function (Fig 1, No 3) can be seen in the bottom-right of the diagram.^{1,23-36} The major noradrenergic influence would in general appear to be that of activation and facilitation. This is evident from effects such as an increase in cerebral blood flow, increased cerebral metabolism, and increased electroencephalographic activity, as well as augmentation of adaptational plasticity, arousal, and vigilance. It is, however, also known that excessive stimulation of the central noradrenergic system may give rise to adverse effects, not only on the structure and function of the noradrenergic system itself, but also on other brain structures and activities.^{18,24,37,38}

There has lately been much interest in the differences between gene expression during wakefulness and gene expression during sleep and it is known that the central noradrenergic system can play a modulating effect on gene expression. It would appear that the activity of the central noradrenergic system during wakefulness contributes to neuronal transcription in favour of synaptic potentiation and to counteracting cellular stress, while its inactivity during sleep could play a permissive role in the increase in brain protein synthesis.³⁹ The central noradrenergic system would appear to be most active in the presence of novel, interesting, stimuli in order to make the rest of the brain more responsive to such stimuli and to speed-up information processing.⁴

The influence of noradrenergic activity on behavioural functions is evident from both animal and human studies. Most of the evidence derived from animal experiments was obtained by subjecting animals to stressful situations. In conditions of severe uncontrollable stress, the reaction known as "learned helplessness" can be observed. This reaction has been described as the animal model of depression in humans and is associated with complete depletion of central noradrenaline stores.^{40,41,42} Descriptions of the effects of acute as well as chronic stress on central noradrenergic activity in brain areas such as the cerebral cortex and on subcortical areas including the hippocampus, the amygdala, the thalamus and the hypothalamus, can be found in excellent reviews by Bremner et al.^{37,38} Acute stress exposure is, for instant, known to be accompanied by a transient increase in the firing rate of neurons of the locus coeruleus and an increase in the release and turnover of noradrenaline at the cerebral projections areas of the noradrenergic neurons. Chronic stress exposure, on the other hand, leads to more permanent changes in the firing rate of locus coeruleus neurons. Presensitization of the central noradrenergic neurons leads to exaggerated stress responses e.g., increased noradrenaline release upon re-exposure. Excessive stimulation may, however, deplete the noradrenergic supply resulting in the typical behavioural pattern of helplessness.³⁷ Both excessive noradrenaline secretion due to previous sensitization, and depletion due to excessive stimulation, can lead to psychiatric disturbances.

Major functions of the noradrenergic system

Noradrenaline has a widespread influence on central nervous system functioning (See Figure 1, No 5). Alterations in central noradrenergic activity has been reported to take place during several behavioural phenomena, including defensive/aggressive behaviour⁴³, perception of a threat^{44,45},

observation of potentially dangerous situations,⁴⁶ during fear and anxiety⁴⁷⁻⁵⁰, during feeding and grooming⁵¹⁻⁵³, with various other types of emotion⁵⁰, during waking and inhibition of REM sleep⁵⁴, in attacking personalities⁵⁵, upon initiation, as well as termination, of food intake⁵⁶, in experiencing rewards and other pleasurable sensations⁵⁵, as well as during arousal, concentration, increased vigilance, memory consolidation, attention, learning, agitation, aggression, resentment, recognition, and emotional analysis pertaining to a stimulus.^{18,23,57-61} The influence of the noradrenergic system on the amygdala and the hippocampus is said to be important for processes like conditioning^{37,38,44}, extinction failure of the conditioned response, memory retention and memory retrieval.^{37,38} The fact that noradrenergic involvement is reported for such a wide scope of functions is not at all surprising when one considers that its primary function comprises the modulation of the activity of other neurons, that it does this in cooperation with other neuromodulatory systems, and that its activity level is in turn influenced by many other systems and signals.

Disorders associated with alterations in central noradrenergic activity

Psychiatric disturbances in which involvement of the noradrenergic system is implicated are listed in Figure 1 (No 5). Over the years abnormal noradrenergic activity has been implicated in many disturbances, some marked by co-dysregulation of other systems and others not. Abnormal noradrenergic activity has for instance been implicated as a major feature in all forms of stress^{18,37,38,62}, in variations in cognitive function²⁵, sensation-seeking⁶³, reward-dependence⁶⁴, pathological gambling⁶⁴, substance abuse⁶⁶, alcohol dependence^{67,68}, aggression^{69,70}, type A personality characteristics⁷¹, borderline personality disorder⁷², suicidal behaviour^{73,74}, eating disorders⁷⁵, impulse control disorders⁷⁶, conduct disorders⁶⁹, ADHD^{69,77}, Tourette's disorder⁶³, paraphilias in males⁷⁸, fear and anxiety disorders^{37,38,69,79,80}, posttraumatic stress disorder^{81,96}, panic disorder^{37,38,69,82}, phobias⁶⁹, depression^{37,69,83-92}, schizophrenia^{69,93} and Alzheimer's disease.^{63,94} Fear and anxiety is almost universally associated with activation of the central noradrenergic system. Central noradrenergic activity in the panic disorder, posttraumatic stress disorder, generalized anxiety disorder, phobic disorders and obsessive-compulsive disorders has been reviewed by Bremner et al.³⁸, and it would appear that the highest activity is seen in panic disorders and the posttraumatic stress syndrome, i.e., those disorders where the stress response is most directly implicated.

It is not always easy to distinguish between cause and effect with regard to the psychoneurological interaction. What is of great interest is the fact that emotions and perceptions can alter, not only the transient physiological processes, but also the more permanent biochemical and structural characteristics of the brain – including that of the central noradrenergic system. This modification of neural structures by the internal and external environment is nothing new and forms part of the early learning processes.⁹⁵ However, it is known that this plasticity persists throughout life and that the central noradrenergic system can be involved in the plasticity of other systems. A role for the noradrenergic system has, amongst others, been described in developmental cortical

plasticity⁹⁶, morphological plasticity during recovery from cortical lesions⁹⁷, the expression of oncogenes in neurons,⁹⁸ prolonged changes in cerebral perfusion^{99,100}, structural changes in astrocytes upon stress-induced noradrenaline secretion¹⁰¹ and noradrenaline-induced changes in blood-brain barrier permeability.^{102,103} A detailed discussion on persisting alterations in central noradrenergic structure and function, or alterations in other brain areas due to a noradrenergic influence, is beyond the scope of this writing, but these phenomena are postulated to be involved in, or to act as trigger for long-term adaptive modification.²⁴ However, more permanent adverse alterations due to modulation of gene transcription are also known to occur and it was shown that it can even be induced by negative psychosocial influences.^{37,38} An overview of the long-term consequences and the structure-function changes of the noradrenergic system in response to controllable and uncontrollable stressors can be found in an excellent writing by Heuter.²⁴ In summary it can be said that changes in the noradrenergic system as a result of controllable stressors can be seen as necessary adaptational processes, i.e., as a form of noradrenergic plasticity. In contrast, stressors perceived as uncontrollable would give rise to anatomical and functional alterations that could cause or predispose to psychopathology (Figure 1 No 4).

Conclusion

Due to its abundant terminations on other central nervous system neurons, the fact that it can propagate impulses through volume transmission and the fact that it interacts with other neuromodulatory systems of the brainstem, activation of the central noradrenergic system has widespread effects on cerebral functioning and on behavior. There can be no doubt that optimal understanding of these neuromodulatory influences and interactions will lead to a much better understanding of many behavioural functions and dysfunctions.

Acknowledgements

Mrs Sigi Dannheimer for assistance with Figure 1.

References

1. Windhorst U. Bilateral organisation of the brain. In: Gregor R, Windhorst U, eds, *Comprehensive Human Physiology*, Vol 1. Berlin: Springer-Verlag; 1996:1137-1160.
2. Jones BE. Arousal systems. *Frontiers Biosci* 2003;8:438-451.
3. Nolte N. Organization of the brainstem. In: *The Human Brain. An introduction to its functional anatomy*. St Louis Missouri: Mosby Inc, 1999:254-282.
4. Bear M, Connors BW, Paradiso MA. *Neuroscience: Exploring the brain*. 2nd ed. Baltimore: Lippincott Williams & Wilkins; 2001.
5. Grant SJ, Huang YH, Redmond DE. Benzodiazepines attenuate single unit activity in the locus coeruleus. *Life Sci* 1980;27:2231.
6. Aston-Jones G. Behavioural functions of locus coeruleus derived from cellular attributes. *Physiol Psychol* 1986;13:118-126.
7. Aston-Jones G, Shipley MT, Chovet G, Ennis M, van Bockstaele E, Pieribone V, Shiekhattar R. Afferent regulation of locus coeruleus neurons: Anatomy, physiology and pharmacology. *Prog Brain Res* 1991;88:47-75.
8. Lambert GW. Paring down on Descartes: a review of brain noradrenaline and sympathetic nervous function. *Clin Exp Pharmacol Physiol* 2001;28(12):979-982.
9. Esler MD, Lambert GW, Ferrier C, Kaye DM, Wallin BG, Kalff V, et al. Central nervous system noradrenergic control of sympathetic outflow in normotensive and hypertensive humans. *Clin Exp Hypertension* 1995;17(1-2):409-423.
10. Holets VR. Anatomy and function of noradrenaline in the mammalian brain. In: *The Pharmacology of Noradrenaline in the Central Nervous System*. Oxford: University Press; 1990:1-27.
11. Svensson TH. Brain noradrenaline and the mechanisms of action of antidepressant drugs. *Acta Psych Scand Suppl*, 2000;402:18-27.
12. Srinivasan J, Schmidt WJ. Functional recovery of locus coeruleus noradrenergic neurons after DSP-4 lesion: effects on dopamine levels and neuroleptic induced-parkinsonian symptoms in rats. *J Neural Transmiss* 2004;111(1):13-26.
13. Feldman S, Weidenfeld J. Involvement of endogenous glutamate in the stimulatory effect of norepinephrine and serotonin on the hypothalamo-pituitary-adrenocortical axis. *Neuroendocrinology* 2004;79(1):43-53.
14. Stevens DR, Kuramasu A, Erikson KS, Selbach O, Haas HL. Alpha 2-adrenergic receptor-mediated presynaptic inhibition of GABAergic IPSPs in rat histaminergic neurons. *Neuropharmacology* 2004;46(7):1018-1022.
15. Stone EA, Lin Y, Ahsan R, Quartermain D. Gross mapping of alpha 1-adrenoceptors that regulate behavioural activation in the mouse brain. *Behav Brain Res* 2004;152(2):167-175.
16. Geschwind N, Behan PO. Left-handedness: Association with immune disease, migraine, and developmental learning disorder. *Proc Natl Acad Sci USA* 1982;79:5097-5100.
17. Geschwind N, Galaburda AM. *Cerebral lateralization: Biological mechanisms, associations, and pathology*. Cambridge, MIT Press, 1987.
18. Chrousos GP, Gold PW. The concept of stress and stress systems disorders. *JAMA* 1992;267:1244-1252.
19. Dunn AJ, Swiergiel AH, Palamourchouk V. Brain circuits involved in corticotropin-releasing factor-norepinephrine interactions during stress. *Ann NY Acad Sci* 2004;1018:25-34.
20. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. *Depression and Anxiety* 2000;12(suppl 1):2-19.
21. Jobe PC. Common pathogenic mechanisms between depression and epilepsy: an experimental perspective. *Epilepsy & Behav* 2003;4(suppl 3):S14-S24.
22. Marien MR, Colpaert FC, Rosenquist AC. Noradrenergic mechanisms in neurodegenerative diseases: a theory. *Brain Res Brain Res Rev* 2004;45(1):38-78.
23. Leon M. Catecholaminergic contributions to early learning. *Adv Pharmacol* 1998;42:961-964.
24. Huether G. The central adaptation syndrome: Psychosocial stress as a trigger for adaptive modifications of brain structure and brain function. *Prog Neurobiol* 1996;48:569-612.
25. Arnsten AF, Steere JC, Jentsch DJ, Li BM. Noradrenergic influences on prefrontal cortical cognitive function: Opposing actions at postjunctional alpha 1 versus alpha 2 adrenergic receptors. *Adv Pharmacol* 1998; 42:764-767.
26. Partonen T. Possible pathophysiological mechanisms regulating food intake in seasonal affective disorder. *Med Hypotheses* 1996;47(3):215-216.
27. Huang QH, Takaki A, Arimura A. Central noradrenergic system modulates plasma interleukin-6 production by peripheral interleukin-1. *Am J Physiol* 1997;273:R731-738.
28. Witte EA, Marrocco RT. Alteration of brain noradrenergic activity in

- rhese monkeys affects the alerting component of overt orientating. Psychopharmacol* 1997;132(4):315-323.
29. Dratman MB, Gordon JT. Thyroid hormones as neurotransmitters. *Thyroid* 1996;6(6):639-647.
30. Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical significance for attention-deficit hyperactivity disorder. *Arch Gen Psychiatry* 1996;53(5):448-455.
31. Berridge CW. Modulation of forebrain electroencephalographic activity and behavioural state by the locus coeruleus - noradrenergic system: Involvement of the medial septal area. *Adv Pharmacol* 1988;42:744-748.
32. Hasselmo ME, Linster C, Patil M, Cekic M. Noradrenergic suppression of synaptic transmission may influence cortical signal-to-noise ratio. *J Neurophysiol* 1997;77(6):3326-3339.
33. Katsuki H, Izumi Y, Zorumski CF. Noradrenergic regulation of synaptic plasticity in the hippocampal CA1 region. *J Neurophysiol* 1997;77(6):3013-20.
34. Michaloudi HC, Mjboudi M, Poulain DA, Papadopoulos GC, Theodosios DT. The noradrenergic innervation of identified hypothalamic magnocellular somata and its contribution to lactation-induced synaptic plasticity. *J Neuroendocrinol* 1997;9(1):17-23.
35. Rorig B, Sutor B. Regulation of gap junction coupling in the developing neocortex. *Mol Neurobiol* 1996;2(3):225-249.
36. Bhatia SC, Saha S, Manchanda SK, Nayar U. Role of midbrain ventro-lateral tegmental area (VLTA) adrenergic mechanisms in facilitation of hypothalamically-induced predatory attack behaviour. *Indian J Exp Biol* 1997;35(4):332-337.
37. Bremner JD, Krystal JH, Southwick SM, Charney D. Noradrenergic mechanisms in stress and anxiety. I. Preclinical studies. *Synapse* 1996;23:28-38.
38. Bremner JD, Krystal JH, Southwick, Charney DS. Noradrenergic mechanisms in stress and anxiety. II. Clinical Studies. *Synapse* 1996;23:39-51.
39. Cirelli C, Tononi G. Locus coeruleus control of state-dependent gene expression. *J Neurosci* 2004;24(23):5410-5419.
40. Petty F, Kramer G, Wilson L, Chae Y-L. Learned helplessness and in vivo hippocampal norepinephrine release. *Pharmacol Biochem Behav* 1993;46:231-235.
41. Seligman EP, David L, Rosenhan. Depression and suicide. In: *Abnormality*. WW Norton and Company Inc; 1998:246.
42. Bloom FE, Lazerson A. Emotions: The highs and the lows of the brain. In *Brain, Mind and Behaviour*. 2nd edition. NY: Freeman and Company; 1996:231.
43. Barret JA, Shaikh MB, Edinger H, Siegel A. The effects of intrahypothalamic injections of norepinephrine upon affective defense behaviour in the cat. *Brain Res* 1987;426:381-384.
44. Rasmussen K, Jacobs BL. Single-unit activity of locus coeruleus neurons in the freely moving cat II. Conditioning and pharmacological studies. *Brain Res* 1986;371:335-344.
45. Rasmussen K, Morilak DA, Jacobs BL. Single-unit activity of locus coeruleus neurons in the freely moving cat I. During naturalistic behaviors and in response to simple and complex stimuli. *Brain Res* 1986;371:324.
46. Levine ES, Litto WJ, Jacobs BL. Activity of cat locus coeruleus noradrenergic neurons during the defense reaction. *Brain Res* 1990;531:189-195.
47. Grant SJ, Redmond DE. Neuronal activity of the locus coeruleus in awake *Macaca arctoides*. *Exp Neurol* 1984;84:701-708.
48. Redmond DE jr. New and old evidence for the involvement of a brain norepinephrine system in anxiety. In: *Phenomenology and Treatment of Anxiety*. Spectrum Pub;1979. pp 153-201.
49. Redmond D, Huang Y. New evidence for a locus coeruleus norepinephrine connection with anxiety. *Life Sci* 1979;25:2149-2162.
50. Abercrombie ED, Jacobs BL. Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats II. Adaptation to chronically presented stressful stimuli. *J Neurosci* 1987;7:2844-2848.
51. Aghajanian G. Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine. *Nature* 1978;276:186-188.
52. Foote SL, Aston-Jones G, Bloom FE. Impulse activity of locus coeruleus neurons in awake rats is a function of sensory stimulation and arousal. *Proc Natl Acad Sci* 1980;USA, 77:3033-3037.
53. Aston-Jones G. Behavioural function of locus coeruleus derived from cellular attributes. *Physiol Psychol* 1986;13:118-126.
54. Rosenzweig MR, Leiman AL, Breedlove SM. Biological rhythms, sleep and dreaming. In: *Biological Psychology*. Massachusetts: Sinauer Ass Inc; 1999. 300-406.
55. Bloom FE, Lazerson A. Emotions: The highs and the lows of the brain. In: *Brain, Mind and Behaviour*. NY: WH Freeman & company; 1996:208-237.
56. Bloom FE, Lazerson A. Homeostasis: Maintaining the internal environment. In: *Brain Mind and Behaviour*. NY: WH Freeman and Company; 1996:399.
57. Le Doux J. Once more with feeling. In: *The Emotional Brain*. London: Phoenix Paperback, 1999:267-303.
58. Donovan BT. Humors, Hormones and the Mind. An approach to the understanding of behaviour. London: MacMillan Press, 1988:159-208.
59. Arnsten AF. Catecholamine regulation of the prefrontal cortex. *J Psychopharm* 1997;11(2):151-162.
60. Sakanaka M, Shibasaki T, Lederis K. Distribution and efferent projections of corticotropin-releasing factor-like immunoreactivity in rat amygdaloid complex. *Brain Res* 1986;382:213-238.
61. Bloom FE, Lazerson A. Learning and memory. In: *Brain, Mind and Behavior*. NY: WH Freeman and Company; 1996:261.
62. Kopin IJ, Eisenhofer G, Goldstein D. In: Chrousos GP, Loriaux DL, Gold PW, editors. *Mechanisms of physical and emotional stress*. NY and London. Plenum Press; 1988:11-23.
63. Gabel S, Stadler J, Bjorn J, Shindlededecker R, Bowden CL. Sensation seeking in psychiatrically disturbed youth: relationship to biochemical parameters and behavior problems. *J Am Acad Child Adol Psychiatry* 1994;33(1):123-129.
64. Garvey MJ, Noyes R jr, Cook B, Blum N. Preliminary confirmation of the proposed link between reward-dependence traits and norepinephrine. *Psychiatry Res* 1996;65(1):61-64.
65. Bergh C, Eklund T, Sodersten P, Nordin C. Altered dopamine function in pathological gambling. *Psychol Med* 1997;27(2):473-475.
66. Gabel S, Stadler J, Bjorn J, Shindlededecker R. Homovanillic acid and dopamine-beta-hydroxylase in male youth: relationships with paternal substance abuse and antisocial behavior. *Am J Drug Alcohol Abuse* 1995;21(3):363-378.
67. De Witte P. The role of neurotransmitters in alcohol dependence: animal research. *Alcohol* 1996;319 (Suppl) 1:13-16.
68. Clayton CJ, Hicks RE. Ethanol, monoamines, and affect. *J Neur Transm Gen Sect* 1994;98(3):169-195.
69. Kaplan HI, Sadock BJ, Grebb JA. *Synopsis of Psychiatry* 7th edition. Behavioural Sciences. Clinical Psychiatry. Baltimore: Maryland, Williams and Wilkins, 1994.
70. Kavoussi R, Armstead P, Coccaro E. The neurobiology of impulsive

- aggression. *Psychiatr Clin North Am* 1997;20(2):395-403.
71. Williams RB jr, Suarez EC, Kuhn CM, Zimmerman EA, Schanberg SM. Biobehavioural basis of coronary-prone behavior in middle men. Part 1: Evidence for chronic SNS activation in Type A. *Psychosom Med* 1991;53:517-527.
72. Figueroa E, Silk KR. Biological implications of childhood sexual abuse in borderline personality disorder. *J Pers Dis* 1997;11(1): 71-92.
73. Arango V, Underwood MD, Mann JJ. Biological alterations in the brainstem of suicides. *Psychiatr Clin North Am* 1997;20(3):581-593.
74. Gilbert C. Major human cancers are preventable: psychological stimuli induce a dopamine-thyroid - immune efficient mechanism. *Psychiatr Clin North Am* 1997;20(3):581-593.
75. Pirke KM. Central and peripheral noradrenaline regulation in eating disorders. *Psychiatry Res* 1996;62(1):43-49.
76. McElroy SL, Pope HG jr, Keck PE jr, Hudson JI, Phillips KA, Strakowski SM. Are impulse-control disorders related to bipolar disorder? *Compr Psychiatry* 1996;37(4):229-240.
77. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: Current perspectives. *J Am Acad Child Adolesc Psychiatry* 1996;35(3):264-272.
78. Kafka MP. A monoamine hypothesis for the pathophysiology of paraphilic disorders. *Arch Sex Behav* 1997;26(4):343-358.
79. Krystal JH, Deutsch DN, Charney DS. The biological basis of panic disorder. *J Clin Psychiatry* 1996;57((Suppl) 10):23-31.
80. Brawman-Mintzer O, Lydiard RB. Biological basis of generalized anxiety disorder. *J Clin Psychiatry* 1997;58(Suppl)3:16-25.
81. Southwick SM, Krystal JH, Bremner JD, Morgan CA, Nicolaou AL, Nagy LM, et al. Noradrenergic and serotonergic function in post-traumatic stress disorder. *Arch Gen Psychiatry* 1997;54(8):749-758.
82. Goddard AW, Charney DS. Toward an integrated neurobiology of panic disorder. *J Clin Psychiatry* 1997;58(Suppl)2:4-11.
83. Meas M, Minner E, Suy C, Vandervorst, Raus J. Coexisting dysregulations of both the sympathoadrenal system and hypothalamic-pituitary-adrenal-axis in melancholia. *J Neural Transm* 1991;85:195-210.
84. Fritze J. The adrenergic-cholinergic imbalance hypothesis of depression: A review and a perspective. *Rev Neurosci* 1993; 4(1):63-93.
85. Sulser F, Sanders-Bush E. The serotonin-norepinephrine link hypothesis of affective disorders: Receptor-receptor interactions in brain. *Adv Exp Med Biol* 1987;221:489-572.
86. Veith RC, Lewis N, Linares OA, Barnes RF, Raskind MA, Villacres EC et al. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics. *Arch Gen Psych* 1994;51(5):411-22.
87. Potter WZ, Manji HK. Catecholamines in depression: An Update. *Clin Chem* 1994;40(2):279-287.
88. Maas JW, Katz MM, Koslow SH, Swann A, Davis JM, Berman N, Bowden CL, Stokes PE, Landis H. Adrenomedullary function in depressed patients. *J Psych Res* 1994;28(4):357-367.
89. Dinan TG. Noradrenergic and serotonergic abnormalities in depression: stress-induced dysfunction? *J Clin Psychiatry* 1996;57(Suppl 4):14-18.
90. Klimek V, Stockmeier C, Overholser J, Meltzer HY, Kalka S, Dilley G, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. *J Neurosci* 1997;17(21):8451-8458.
91. Mokrani MC, Duval F, Crocq MA, Bailey P, Macher JP. HPA axis dysfunction in depression: Correlation with monoamine system abnormalities. *Psychoneuroendocrinol* 1997;22 (Suppl)1:S63-68.
92. Kelly CB, Cooper SJ. Plasma noradrenaline reponse to electroconvulsive therapy in depressive illness. *Br J Psychiatry* 1997;171:182-186.
93. Carlsson A, Hansson LO, Waters N, Carlsson ML. Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications. *Life Sci* 1997;61(2):75-94.
94. Palmer AM. Neurochemical studies of Alzheimer's disease. *Neurodegeneration* 1996;5(4):381-91.
95. Schwartz JP. Development and plasticity. Overview. *Adv Pharmacol* 1998;42:877-882.
96. Marshall KC, Christie MJ, Finlayson PG, Williams LT. Developmental aspects of the locus coeruleus noradrenaline system. *Prog Brain Res* 1991;88:173-185.
97. Boyeson MG, Krobert KA. Cerebellar norepinephrine infusions, facilitate recovery after sensorimotor cortex injury. *Brain Res Bull* 1992;29:435-439.
98. Vaccarino FM, Hayward MD, Lee MW, Harigan DJ, Duman RS, Nestler EJ. Induction of immediate early genes by c-AMP in primary cultures of neurons from rat cerebral cortex. *Molec Brain Res* 1993;19:76-82.
99. Bryan RMJ jr. Cerebral blood flow and energy metabolism during stress. *Am J Physiol* 1990;259:H269-H280.
100. Bryan RM, Lehmann RAW. Cerebral glucose utilization after aversive conditioning and during conditioned fear in rat. *Brain Res* 1988;444:17-24.
101. Stone AA, Ariano MA. Are glial cells targets of the cerebral adrenergic systems? *Brain Res Rev* 1989;14:297-308.
102. Nathanson JA. Adrenergic receptors in brain microvessels. *Trends Neurol Sci* 1983;4:422-424.
103. Ohata M, Takei HO, Fredericks WR, Rapoport SJ. Effects of immobilization stress on cerebral blood flow and cerebrovascular permeability in spontaneously hypertensive rats. *J Cereb Blood Flow Metab* 1982;2:373-379.